#USA #Chicago #Seegene #CURECA #STAgora

Seegene Unveils Transformative PCR Automation

At the upcoming ADLM 2025 conference in Chicago, Seegene Inc., a frontrunner in molecular diagnostics, is set to showcase its innovative fully automated PCR testing system, CURECA™. This groundbreaking device not only signifies a major step forward in diagnostic technology but also aims to redefine industry standards for efficiency and precision in laboratory testing. The event, which runs from July 28 to 31, will be the first opportunity for professionals to witness CURECA™ in action, as Seegene illustrates its capabilities to revolutionize PCR workflows.

The Future of PCR Testing

CURECA™ stands out as the world’s first fully unmanned automated system for PCR testing. This integrated solution covers every aspect of the PCR process—from specimen storage and pre-treatment through to nucleic acid extraction, amplification, and the final result analysis—all without human intervention. Operating continuously around the clock, it minimizes the risk of human error, thus enhancing the reliability of test results dramatically.

Among its main features is a state-of-the-art prep module designed to automate the crucial yet often challenging pre-treatment phase, which is notorious for requiring significant manual labor and posing a high risk of inconsistencies, especially with various sample types like urine, blood, sputum, and stool. By using CURECA™, laboratory technicians can bypass tedious manual tasks and focus on higher-level analytic responsibilities.

The innovations featured in CURECA™ tackle longstanding hurdles associated with laboratory operations. For instance, one persistent challenge has been the handling of stool samples due to their complex properties. With its advanced prep technologies, CURECA™ facilitates full automation of the pre-treatment process, enhancing both sample throughput and operational efficiency. This breakthrough not only alleviates labor demands but also transforms the roles of personnel in labs with high-volume testing needs.

Beyond PCR Testing

In addition, the capabilities of CURECA™ extend beyond PCR diagnostics. The prep module is versatile enough to support pre-treatment processes needed in clinical chemistry and immunoassays, highlighting Seegene’s commitment to wider automation in diagnostics.

STAgora™: Integration of Diagnostic Data

Alongside the formal introduction of CURECA™, Seegene will debut STAgora™, a powerful statistical platform capable of collecting and analyzing real-time PCR data that will support clinical decisions. By aggregating data from hospitals worldwide, this platform offers valuable insights into infection trends, positivity rates, and co-infection patterns tailored for clinical application.

By comparing test results with local epidemiology, healthcare providers can enhance diagnostic accuracy and develop targeted treatment strategies. This data-driven approach not only improves individual patient outcomes but also broadens community health responses to infection dynamics.

Seegene's Vision for Global Collaboration

With the launch of these revolutionary technologies, Seegene aims to expand access to CURECA™ and STAgora™ through early pilot programs and collaborations. The success witnessed at the recent ESCMID Global 2025 conference demonstrated immense interest in CURECA™, prompting Seegene to focus on increasing its research, development, and manufacturing capabilities within the United States.

Daniel Shin, Seegene’s Executive Vice President, asserts that CURECA™ and STAgora™ are redefining standards in clinical diagnostics, stating,